{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:23:25Z","timestamp":1790519005824,"version":"4.1.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Miltefosine is the only recognized oral agent with potential to treat leishmaniasis. Miltefosine had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and Bangladesh, but high rates of clinical failures have been recently reported. Moderate efficacy has been observed for VL in East Africa, whereas data from Mediterranean countries and Latin America are scarce. Results have not been very promising for patients coinfected with VL and human immunodeficiency virus. However, miltefosine's long half-life and its oral administration could make it a good option for maintenance prophylaxis. Good evidence of efficacy has been documented in Old World cutaneous leishmaniasis (CL), and different cure rates among New World CL have been obtained depending on the geographical areas and species involved. Appropriate regimens for New World mucocutaneous leishmaniasis need to be established, although longer treatment duration seems to confer better results. Strategies to prevent the development and spread of miltefosine resistance are urgently needed.<\/jats:p>","DOI":"10.1093\/cid\/civ004","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T22:03:55Z","timestamp":1421705035000},"page":"1398-1404","source":"Crossref","is-referenced-by-count":93,"title":["Miltefosine for Visceral and Cutaneous Leishmaniasis: Drug Characteristics and Evidence-Based Treatment Recommendations"],"prefix":"10.1093","volume":"60","author":[{"given":"Bego\u00f1a","family":"Monge-Maillo","sequence":"first","affiliation":[{"name":"Ram\u00f3n y Cajal Hospital Tropical Medicine Centre, Infectious Diseases Department, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"L\u00f3pez-V\u00e9lez","sequence":"additional","affiliation":[{"name":"Ram\u00f3n y Cajal Hospital Tropical Medicine Centre, Infectious Diseases Department, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,1,18]]},"reference":[{"key":"2024111411394257900_CIV004C1","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"The WHO Leishmaniasis Control Team: leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"2024111411394257900_CIV004C2","article-title":"Global plan to combat neglected tropical diseases 2008\u20132015","author":"World Health Organization"},{"key":"2024111411394257900_CIV004C3","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s40265-013-0133-0","article-title":"Therapeutic options for visceral leishmaniasis","volume":"73","author":"Monge-Maillo","year":"2013","journal-title":"Drugs"},{"key":"2024111411394257900_CIV004C4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s40265-013-0132-1","article-title":"Therapeutic options for Old World cutaneous leishmaniasis and New World cutaneous and mucocutaneous leishmaniasis","volume":"73","author":"Monge-Maillo","year":"2013","journal-title":"Drugs"},{"key":"2024111411394257900_CIV004C5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","article-title":"Infectious Diseases Society of America: guide to development of practice guidelines","volume":"32","author":"Kish","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1086\/656735","article-title":"Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines","volume":"51","author":"Khan","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"2024111411394257900_CIV004C7","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.trstmh.2006.03.009","article-title":"Miltefosine\u2014discovery of the antileishmanial activity of phospholipid derivatives","volume":"100","author":"Croft","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024111411394257900_CIV004C8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0166-6851(82)90042-1","article-title":"Metabolism of 1-0-[1\u2032-14C]octadecyl-sn-glycerol in Leishmania donovani promastigotes. Ether lipid synthesis and degradation of the ether bond","volume":"5","author":"Herrmann","year":"1982","journal-title":"Mol Biochem Parasitol"},{"key":"2024111411394257900_CIV004C9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.36.8.1630","article-title":"Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice","volume":"36","author":"Kuhlencord","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411394257900_CIV004C10","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"2024111411394257900_CIV004C11","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1128\/AAC.44.11.3235-3236.2000","article-title":"Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine","volume":"44","author":"Murray","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411394257900_CIV004C12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0035-9203(99)90192-X","article-title":"Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis","volume":"93","author":"Schmidt-Ott","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024111411394257900_CIV004C13","article-title":"Application for inclusion of miltefosine on WHO Model List of Essential Medicines","year":"2010"},{"key":"2024111411394257900_CIV004C14","article-title":"Paladin announces extension of the Impavido \u00ae PDUFA date by three months","author":"Paladin Labs"},{"key":"2024111411394257900_CIV004C15","article-title":"News and events\u2014FDA News Release","author":"US Food and Drug Administration"},{"key":"2024111411394257900_CIV004C16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/648726","article-title":"Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan","volume":"50","author":"van Thiel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/0022-3859.123161","article-title":"Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment","volume":"59","author":"Pandey","year":"2013","journal-title":"J Postgrad Med"},{"key":"2024111411394257900_CIV004C18","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024111411394257900_CIV004C19","first-page":"287","article-title":"Miltefosine (Impavido, Miltex)","volume-title":"Antibiotic manual. A guide to commonly used antimicrobials","author":"Schlossberg","year":"2011"},{"key":"2024111411394257900_CIV004C20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4269\/ajtmh.13-0096","article-title":"In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis","volume":"89","author":"Prajapati","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C22","doi-asserted-by":"crossref","first-page":"e00611","DOI":"10.1128\/mBio.00611-13","article-title":"Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain","volume":"4","author":"Rai","year":"2013","journal-title":"MBio"},{"key":"2024111411394257900_CIV004C23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2007.05.007","article-title":"Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo","volume":"30","author":"Seifert","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2024111411394257900_CIV004C24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1128\/AAC.01694-08","article-title":"Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug","volume":"53","author":"Sanchez-Canete","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411394257900_CIV004C25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure","volume":"210","author":"Dorlo","year":"2014","journal-title":"J Infect Dis"},{"key":"2024111411394257900_CIV004C27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4269\/ajtmh.2012.12-0022","article-title":"In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis\u2014status of newly introduced drugs","volume":"87","author":"Prajapati","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C28","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.trstmh.2006.02.011","article-title":"Oral miltefosine for the treatment of Indian visceral leishmaniasis","volume":"100","author":"Sundar","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024111411394257900_CIV004C29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"2024111411394257900_CIV004C30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"2024111411394257900_CIV004C31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/318122","article-title":"Short-course of oral miltefosine for treatment of visceral leishmaniasis","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.inf.0000066877.72624.cb","article-title":"Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis","volume":"22","author":"Sundar","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411394257900_CIV004C33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/380638","article-title":"Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India","volume":"38","author":"Bhattacharya","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/BF02763048","article-title":"Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study","volume":"73","author":"Singh","year":"2006","journal-title":"Indian J Pediatr"},{"key":"2024111411394257900_CIV004C35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4269\/ajtmh.2011.10-0661","article-title":"Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh","volume":"85","author":"Rahman","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/505217","article-title":"A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection","volume":"43","author":"Ritmeijer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C37","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"2024111411394257900_CIV004C39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trstmh.2010.10.008","article-title":"Ambisome plus miltefosine for Indian patients with kala-azar","volume":"105","author":"Sundar","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024111411394257900_CIV004C40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1745-6215-12-166","article-title":"Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial","volume":"12","author":"Omollo","year":"2011","journal-title":"Trials"},{"key":"2024111411394257900_CIV004C41","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1086\/425359","article-title":"Miltefosine compassionate use program: oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection","volume":"39","author":"Sindermann","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00365540701466215","article-title":"Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients","volume":"40","author":"Troya","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"2024111411394257900_CIV004C43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4269\/ajtmh.2010.09-0594","article-title":"Visceral leishmaniasis treated with antimonials\/paromomycin followed by itraconazole\/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient","volume":"83","author":"Barragan","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/00365540701787800","article-title":"Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients","volume":"40","author":"Marques","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"2024111411394257900_CIV004C45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.virol.2012.05.032","article-title":"Miltefosine represses HIV-1 replication in human dendritic cell\/T-cell cocultures partially by inducing secretion of type-I interferon","volume":"432","author":"Garg","year":"2012","journal-title":"Virology"},{"key":"2024111411394257900_CIV004C46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-4632.2007.03153.x","article-title":"First case of typical Old World cutaneous leishmaniasis treated with miltefosine","volume":"46","author":"Stojkovic","year":"2007","journal-title":"Int J Dermatol"},{"key":"2024111411394257900_CIV004C47","doi-asserted-by":"crossref","first-page":"e1436","DOI":"10.1371\/journal.pntd.0001436","article-title":"Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine","volume":"5","author":"Dorlo","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2024111411394257900_CIV004C48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.actatropica.2007.05.005","article-title":"Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran","volume":"103","author":"Mohebali","year":"2007","journal-title":"Acta Trop"},{"key":"2024111411394257900_CIV004C49","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1610-0387.2008.06779.x","article-title":"Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine","volume":"6","author":"Neub","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024111411394257900_CIV004C50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1155\/2008\/802710","article-title":"Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan","volume":"19","author":"Keynan","year":"2008","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2024111411394257900_CIV004C51","first-page":"103","article-title":"Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis","volume":"33","author":"Ramesh","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"2024111411394257900_CIV004C52","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.trstmh.2005.09.015","article-title":"Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine","volume":"100","author":"Sundar","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024111411394257900_CIV004C53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2133.2011.10402.x","article-title":"Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis","volume":"165","author":"Ramesh","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024111411394257900_CIV004C54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/tmi.12015","article-title":"Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial","volume":"18","author":"Sundar","year":"2013","journal-title":"Trop Med Int Health"},{"key":"2024111411394257900_CIV004C55","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1086\/322689","article-title":"Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent","volume":"33","author":"Soto","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C56","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","article-title":"Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis","volume":"83","author":"Velez","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C58","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4269\/ajtmh.2008.78.210","article-title":"Efficacy of miltefosine for Bolivian cutaneous leishmaniasis","volume":"78","author":"Soto","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C59","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2024111411394257900_CIV004C60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C61","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1365-4632.2011.04987.x","article-title":"Treatment of imported New World cutaneous leishmaniasis in Germany","volume":"50","author":"Harms","year":"2011","journal-title":"Int J Dermatol"},{"key":"2024111411394257900_CIV004C62","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jir816","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children","volume":"205","author":"Rubiano","year":"2012","journal-title":"J Infect Dis"},{"key":"2024111411394257900_CIV004C63","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/510588","article-title":"Treatment of Bolivian mucosal leishmaniasis with miltefosine","volume":"44","author":"Soto","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024111411394257900_CIV004C64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4269\/ajtmh.2009.81.387","article-title":"Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia","volume":"81","author":"Soto","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C65","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.4269\/ajtmh.2006.75.1074","article-title":"Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment","volume":"75","author":"Calvopina","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411394257900_CIV004C66","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-4632.2006.02751.x","article-title":"Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report","volume":"45","author":"Zerpa","year":"2006","journal-title":"Int J Dermatol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/9\/1398\/1129344\/civ004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/9\/1398\/1129344\/civ004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:47:24Z","timestamp":1731566844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/60\/9\/1398\/404258"}},"subtitle":[],"editor":[{"given":"Louis D.","family":"Saravolatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,18]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,1,18]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ004","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,5,1]]},"published":{"date-parts":[[2015,1,18]]}}}